Inhalyx Biotech

Background

Inhalyx Biotech is a biotechnology company specialising in inhaled therapies for respiratory diseases, including Cystic Fibrosis and non-CF Bronchiectasis. Among its key treatments is Colifin, which exemplifies the company’s commitment to improving patient outcomes through advanced respiratory technologies.

The company’s core mission is to drive progress in respiratory medicine. Inhalyx Biotech is dedicated to the ongoing development of innovative therapies and the pursuit of new opportunities to address the unmet needs of patients suffering from chronic respiratory conditions. With a strong emphasis on scientific rigor and a patient-centric approach, the company strives to advance the standard of care in respiratory health.